MBRX   $0.6016  6.12% Market Closed After Close 0.5703 -5.20%

Moleculin Biotech, Inc.
Last Events:

2023-08-09 Trend pattern changed from расширяющаяся формация to расходящийся треугольник.

2023-08-09 Signal in Stochastic changed from bearish recovery to bullish reversal. The stochastic indicator is in the lower part of the neutral territory and left the oversold territory. These factors indicate that perhaps the downside trend is coming to an end price will probably head north Last signal: main and signal line crossing.

2023-08-09 Signal in MACD changed from bearish reversal to bullish recovery. Oscillator MACD is in the positive territory it's lower than the signal line and grows. These factors mean that positive mood prevails, but this trend does not have a significant strength. Last signal: main and signal line crossing.

2023-08-09 Signal in RSI changed from bearish recovery to bullish. RSI indicator is in the upper part of the neutral territory and it heading north. These factors indicate that positive dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-09 Signal in EMA20 changed from bearish reversal to bullish reversal. The price is trying to cross up the moving average line If the intersection will be successful, then an upside trend can be formed.

2023-08-06 Signal in RSI changed from bearish weakening to bearish recovery. RSI indicator is in the lower part of the neutral territory and it heading south. These factors indicate that negative dynamics is recovering. Last signal: exit from the overbought zone.

2023-08-05 Signal in RSI changed from bearish to bearish weakening. RSI indicator is in the lower part of the neutral territory and it heading north. These factors indicate that the upside trend is forming Last signal: exit from the overbought zone.

2023-08-04 Trend pattern changed from расширяющийся канал to расширяющаяся формация.


Current temperature: 5.86
ST: 0, Cor:

Analyst Recommendations:
Number of estimates 3
Target Price Mean 12.00
Mean unverified/preliminary 12.00 / 12.00
Target Price Low / High 2.00 / 31.00
Median / STD DEV 3.00 / 16.46
Tech Forecasts:
More signals
  < 1M 1-3M > 3M
total Buy Buy ActivelyBuy
rsi Sell Buy None
macd None ActivelyBuy None
stoch ActivelyBuy None None
ma20 None Buy ActivelyBuy
ma50 ActivelyBuy None None
ma100 Buy Buy ActivelyBuy
Candlestick PatternSept. 25, 2026 Three Stars -
ISIN US60855D4088
ceo Mr. Walter V. Klemp
Website https://moleculin.com
Moleculin Biotech, Inc., a clinical stage pharmaceutical company, focuses on the development of drug candidates for the treatment of cancers and viruses. Its lead drug candidate is Annamycin, which is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma metastasized to the lungs. The company is also developing WP1066, an immune/transcription modulator designed to inhibit phosphorylated signal transducer and activator of transcription and other oncogenic transcription factors targeting brain tumors, and pancreatic and other cancers. In addition, it develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat viruses, as well as cancer indications, including brain tumors, and pancreatic and other cancers. The company was incorporated in 2015 and is headquartered in Houston, Texas.